Arrowhead outlines potential Q2 2027 sHTG launch for REDEMPLO and reiterates $3B-$4B U.S. sales opportunity

Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q4 fiscal 2026

Management View

• “Arrowhead has fundamentally changed over the past 12 months.” (Chairman, CEO & President Dr. Christopher Anzalone) He tied the near-term equity story to execution in commercialization, saying, “Simply put, commercial progress with REDEMPLO is critical.” (CEO Anzalone)

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.